Cargando…
A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines
BACKGROUND: Immunogenicity of inactivated SARS-CoV-2 vaccine has waning antibody over time. With the emergence of the SARS-CoV-2 delta variant, which requires higher neutralizing antibody to prevent infection, a booster dose is needed. OBJECTIVE: To evaluate immunogenicity and reactogenicity of stan...
Autores principales: | Nanthapisal, Sira, Puthanakit, Thanyawee, Jaru-Ampornpan, Peera, Nantanee, Rapisa, Sodsai, Pimpayao, Himananto, Orawan, Sophonphan, Jiratchaya, Suchartlikitwong, Pintip, Hiransuthikul, Narin, Angkasekwinai, Pornpimon, Tangsathapornpong, Auchara, Hirankarn, Nattiya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947780/ https://www.ncbi.nlm.nih.gov/pubmed/35341647 http://dx.doi.org/10.1016/j.vaccine.2022.03.036 |
Ejemplares similares
-
A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222
por: Nantanee, Rapisa, et al.
Publicado: (2022) -
Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac
por: Nantanee, Rapisa, et al.
Publicado: (2022) -
Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents
por: Puthanakit, Thanyawee, et al.
Publicado: (2022) -
Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance
por: Nantanee, Rapisa, et al.
Publicado: (2023) -
Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents
por: Puthanakit, Thanyawee, et al.
Publicado: (2022)